Dose-intensive therapy in lung cancer

Area of Science:

• Oncology
• Cancer Research
• Pulmonology

Background:

• Lung cancer remains a leading cause of cancer mortality worldwide, with limited 5-year survival rates.
• Chemotherapy is established for small-cell lung cancer (SCLC) but less effective for non-SCLC (NSCLC).
• Smoking-related comorbidities complicate intensive therapies for lung cancer patients.

Purpose of the Study:

• To discuss strategies for intensifying induction therapy and combination chemotherapy for SCLC and NSCLC.
• To evaluate the role of high-dose therapy and stem cell purging in lung cancer treatment.
• To explore methods for targeting minimal residual tumor (MRT) cells, including biologic therapies.

Main Methods:

• Review of dose-intensive chemotherapy strategies, including multicycle regimens and chest radiotherapy.
• Performance of stem-cell autografts in SCLC patients responding to conventional-dose therapy.
• Analysis of minimal residual tumor (MRT) detection and characterization.

Main Results:

• In SCLC, combination chemotherapy provides palliation but long-term survival remains low (20-40% for limited disease, <5% for extensive disease at 2 years).
• High-dose chemotherapy with autologous stem-cell transplantation in SCLC patients resulted in 52% disease-free survival at a minimum of 23 months follow-up.
• Approximately 20% of extensive-disease SCLC patients remained progression-free for over 2 years after high-dose therapy.

Conclusions:

• Dose-intensive chemotherapy followed by autologous stem-cell transplantation demonstrates significant potential for improving long-term outcomes in SCLC.
• Further research is needed to evaluate the role of thoracic radiation dose intensity and stem cell graft purification.
• Targeting minimal residual tumor (MRT) cells through novel strategies may enhance treatment efficacy for lung cancer.